NCT02645253View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 12, 2016

Primary Completion Date

April 17, 2016

Study Completion Date

April 17, 2016

Conditions
AsthmaChronic Obstructive Pulmonary Disease COPD
Interventions
DRUG

AZD7594 inhalation powder (200 μg)

200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)

DRUG

AZD7594 inhalation powder (400 μg)

Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI

DRUG

AZD7594 pressurized inhalation suspension (200 μg)

400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)

DRUG

AZD7594 placebo inhalation powder

AZD7594 placebo inhalation powder via multi-dose DPI

DRUG

AZD7594 placebo pressurized inhalation suspension

AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY